Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer
Cancer Medicine ( IF 4 ) Pub Date : 2024-04-23 , DOI: 10.1002/cam4.7032
Wei Xu _{1,

2} , Jing Zhao ₁ , Fang Luan ₁ , Zhizhao Zhang ₁ , Lei Liu ₁ , Hui Zhao ₁ , Bin Feng ₁ , Guobin Fu _{1,

2,

3}

Affiliation

BackgroundSevere acute respiratory syndrome coronavirus 2 disease (COVID‐19) has caused a worldwide challenging and threatening pandemic. We aimed to assess the safety and efficacy of the COVID‐19 vaccines in Non‐Small Cell Lung Cancer (NSCLC) patients.MethodsPatient self‐reported adverse events related to vaccines were recorded by follow‐up through a uniform questionnaire. Survival analysis was performed by Kaplan–Meier method. A multivariate analysis was performed by the Cox proportional hazard regression model to determine the effect of each variable on the survival of lung cancer patients.ResultsA total of 860 patients with NSCLC on treatment were enrolled. Mean age was 57 years in patients with early stage group and 62 years in advanced stage group. The vaccination rate was 71.11% for early‐stage patients and 19.48% for advanced‐stage patients; most of them (86.5%) received the COVID‐19 inactivated virus (Vero cell) vaccine (Coronavac; Sinovac). The most common systemic adverse reaction was weakness. The main reason for vaccine refusal in those unvaccinated patients was concern about the safety of vaccination in the presence of a tumor and undergoing treatment (56.9% and 53.4%). The 1‐year disease‐free survival (DFS) rate was 100% for vaccinated and 97.4% for unvaccinated early‐stage patients. Then we compared the progression‐free survival (PFS) of vaccinated (median PFS 9.0 months) and unvaccinated (median PFS 7.0 months) advanced stage patients (p = 0.815). Advanced NSCLC patients continued to be divided into groups receiving radio‐chemotherapy, immunotherapy, and targeted therapy, with no statistical difference in PFS between the groups (p > 0.05). The median overall survival (OS) of vaccinated patients was 20.5 months, and that of unvaccinated patients was 19.0 months (p = 0.478) in advanced NSCLC patients.ConclusionsCOVID‐19 vaccination is safe for Chinese NSCLC patients actively receiving different antitumor treatments without increasing the incidence of adverse reactions, and vaccination does not affect cancer patient survival.

更新日期：2024-04-23

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>